Resources – OPUS Clinical Study

CA

North America

United States

About OPUS Program
What is Clinical Study? About the OPUS Clinical Study What is involved in taking part
Are you Eligible?
Recruiting Countries
Find Your Nearest Study Site
Others
Glossary FAQs Resources

It is normal to have a lot of questions before you decide whether or not to take part in a clinical study.

Patient Organizations

Colors of Lupus Nevada is a non-profit organization dedicated to improving the quality of life for individuals affected by Lupus in Las Vegas, Nevada. We are passionate about providing urgently needed services, programs, and support to patients while raising awareness of Lupus among medical professionals and the general public.

The Lupus and Allied Diseases Association (LADA) is a national patient-led organization dedicated to improving access to care and quality of life by fostering collaboration among stakeholders, promoting unity in the community, and wielding the patient voice as a catalyst to advance innovative advocacy, education, awareness and biomedical research initiatives.

Leaving the OPUS Study website

You are moving from OPUS Study website to an affiliated website or a third party website which is solely responsible for its content, including compliance with applicable guidelines in certain regions. Links to OPUS Study affiliated websites and third party websites are provided as a resource to our visitors and may not be governed by the same regulatory requirements that apply to this website. Affiliated website or Third party websites are subject to their own terms, notices and data protection practices. In addition, if Affiliated website or Third party websites are subject to the laws of other countries, regulatory requirements for data protection or medical practices may differ among countries and the information provided may not be suitable for use in your country.

Cookie Policy
Privacy Policy
Terms and Conditions

Cenerimod is an investigational drug currently undergoing Phase 3 clinical trials. It has not been approved for use in any country. Viatris and/or Idorsia does not make, and expressly disclaims, any representations or warranties of any kind, either express or implied (including, without limitation, any implied warranties of content or non-infringement) with regard to any such information disseminated through this program/presentation/poster, including its accuracy and/or completeness. The viewers assume all risk for use of the information and the content provided in this program/presentation/poster. In no event shall Viatris and/or Idorsia or any of its affiliates, directors, employees, officers, consultants and service providers be liable, directly or indirectly, for any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; whether or not the user has been informed of the possibility in advance; and whether or not resulting from or in connection with the creation or use of or reliance upon the program/presentation/poster.

The sponsor of the named study is currently Idorsia Pharmaceuticals Ltd. As of March 18, 2024, Viatris Inc. entered into a global collaboration with Idorsia, which includes Cenerimod, and the study sponsorship is expected to be transferred to Viatris soon.

Leaving the OPUS Study website

You are moving from OPUS Study website to an affiliated website or a third party website which is solely responsible for its content, including compliance with applicable guidelines in certain regions. Links to OPUS Study affiliated websites and third party websites are provided as a resource to our visitors and may not be governed by the same regulatory requirements that apply to this website. Affiliated website or Third party websites are subject to their own terms, notices and data protection practices. In addition, if Affiliated website or Third party websites are subject to the laws of other countries, regulatory requirements for data protection or medical practices may differ among countries and the information provided may not be suitable for use in your country.